Health Technology Eisai Co., Ltd. Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
Mar 2020
JPY USD Revenue 695,621M 6,397.94M Gross Profit 510,352M 4,693.93M Operating income 138,679M 1,275.49M Income before tax 128,063M 1,177.85M Net income 121,767M 1,119.94M EBITDA 172,379M 1,585.44M Diluted EPS 424.79 3.90 Dividends Per Share 160 1.47 Total Assets 1,062.14B 9,838.72M Total liabilities 359,509M 3,330.17M Total equity 678,127M 6,281.57M Operating cash flow 102,782M 945.33M Currency in JPY Currency in USD
Historical Data Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
547,922M
539,097M
600,054M
642,834M
695,621M
Gross Profit
339,839M
331,091M
386,599M
446,436M
510,352M
Operating income
42,779M
51,205M
75,595M
99,921M
138,679M
Income before tax
50,473M
57,668M
76,803M
89,454M
128,063M
Net income
54,933M
39,359M
51,845M
63,386M
121,767M
EBITDA
76,843M
77,689M
101,778M
126,762M
172,379M
Diluted EPS
191.76
137.41
180.97
221.11
424.79
Dividends Per Share
150
150
150
150
160
Total Assets
973,987M
1,030.76B
1,049.03B
1,071.52B
1,062.14B
Total liabilities
397,159M
428,172M
434,934M
419,539M
359,509M
Total equity
573,660M
584,630M
593,582M
628,120M
678,127M
Operating cash flow
95,617M
75,851M
149,649M
103,714M
102,782M
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
4,562.81M
4,978.38M
5,414.06M
5,796.79M
6,397.94M
Gross Profit
2,830.00M
3,057.51M
3,488.14M
4,025.76M
4,693.93M
Operating income
356.24M
472.86M
682.06M
901.04M
1,275.49M
Income before tax
420.31M
532.54M
692.96M
806.65M
1,177.85M
Net income
457.45M
363.46M
467.77M
571.58M
1,119.94M
EBITDA
639.90M
717.43M
918.30M
1,143.08M
1,585.44M
Diluted EPS
1.59
1.26
1.63
1.99
3.90
Dividends Per Share
1.24
1.38
1.35
1.35
1.47
Total Assets
8,665.75M
9,250.32M
9,863.94M
9,680.80M
9,838.72M
Total liabilities
3,533.60M
3,842.51M
4,089.64M
3,790.38M
3,330.17M
Total equity
5,103.96M
5,246.61M
5,581.39M
5,674.84M
6,281.57M
Operating cash flow
796.24M
700.45M
1,350.22M
935.24M
945.33M
Valuation Measures
Mar 2020
PER 18.66 ROA 11.41% ROE 18.64% Operating margin 19.93% Profit margin 17.50%
Key executives
Chief Executive Officer & Representative Director:
Haruo Naito
COO, Representative Executive Officer & Head-China:
Yasushi Okada
Chief Financial Officer:
Ryohei Yanagi
Chief Medical Officer & Managing Executive Officer:
Edward Stewart Geary
Chief Medical & Chief Clinical Officer-Neurology:
Lynn D. Kramer Shareholders
Wellington Management Co. LLP (8.6%)
Nomura Asset Management Co., Ltd. (6.1%)
Government of Japan (5.0%)
Nippon Life Insurance Co. (4.1%)
Asset Management One Co., Ltd. (3.4%)
Eisai Co., Ltd. (3.3%)
Nikko Asset Management Co., Ltd. (2.8%)
Daiwa Asset Management Co. Ltd. (2.8%)
The Vanguard Group, Inc. (2.5%)
Resona Holdings, Inc. (2.2%)
Contact Details Website: http://www.eisai.co.jp Address:
4-6-10 Koishikawa,
Bunkyo-Ku,
Tokyo,
112-8088,
Japan
Phone:
+81.3.3817.3700
Related Companies
Eisai Europe Ltd.
Eisai LLC
Eisai Machinery China Co. Ltd.
Eisai Laboratorios S de RL de CV
Eisai GesmbH
Eisai Farmaceutica, Unipessoal Lda.
Eisai Clinical Research Singapore Pte Ltd.
Eisai Ltd. (Canada)
Eisai SA/NV
Eisai (Malaysia) Sdn. Bhd.
Eisai (Thailand) Marketing Co. Ltd.
Eisai AB
Eisai Pharma AG
Eisai (Singapore) Pte Ltd.
Eisai Co. Ltd. /Misato Factory/
Eisai Board Incentive Plan
Eisai Corporate Pension Fund
Eisai Pension Fund
Eisai China, Inc.
H3 Biomedicine, Inc.
Eisai R&D Management Co., Ltd.
Herusu Co., Ltd.
Gakuen Shoji Co., Ltd.
PT Eisai Indonesia
Eisai Taiwan, Inc.
Eisai (Hong Kong) Co. Ltd.
Eisai Australia Pty Ltd.
Eisai Pharmaceuticals India Pvt Ltd.
Eisai GmbH
Eisai SRL
Competitors
JW Holdings Corporation
Celltrion Pharm Inc.
Ipsen SA
Boryung Pharmaceutical Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A
Denali Therapeutics Inc.
Arcutis Biotherapeutics Inc
Exelixis, Inc.
Blueprint Medicines Corp.
Oncternal Therapeutics, Inc.
Genkyotex SA
Vivoryon Therapeutics AG
ACADIA Pharmaceuticals Inc.
Spring Bank Pharmaceuticals, Inc.
Minerva Neurosciences Inc
Aptinyx Inc
Xenon Pharmaceuticals Inc.
Aprea Therapeutics, Inc.
Genfit SA
Aduro BioTech, Inc.
Aeolus Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Seattle Genetics, Inc.
Cortexyme, Inc.
InnoCare Pharma Limited
AC Immune SA
AVEO Pharmaceuticals, Inc.
Heron Therapeutics Inc
Phathom Pharmaceuticals, Inc.
Marinus Pharmaceuticals Inc
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 29 Sep, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
